(BN) Danone - Overview
Stock: Yogurt, Mineral Water, Baby Formula, Plant-Based
Dividends
| Dividend Yield | 2.86% |
| Yield on Cost 5y | 4.78% |
| Yield CAGR 5y | 2.60% |
| Payout Consistency | 99.3% |
| Payout Ratio | 75.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 26.2% |
| Relative Tail Risk | -9.78% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.18 |
| Alpha | 5.35 |
| Character TTM | |
|---|---|
| Beta | -0.227 |
| Beta Downside | -0.137 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.29% |
| CAGR/Max DD | 0.75 |
Description: BN Danone January 29, 2026
Danone S.A. (ticker BN) is a French multinational food-and-beverage group that sells a broad portfolio-including dairy, plant-based, specialized nutrition, and bottled water-across 5 continents through retail, foodservice, health-care, and e-commerce channels. Its operations are organized into three segments: Essential Dairy & Plant-Based, Specialized Nutrition, and Waters.
Key recent metrics (FY 2023): revenue €27.2 bn (up 3.1 % YoY), adjusted EBIT margin 7.4 % (down 0.6 pp from 2022), and free cash flow €2.1 bn. The Waters segment delivered the strongest top-line growth (+6 % YoY) driven by premium bottled-water demand in emerging markets, while the Essential Dairy & Plant-Based segment faced modest volume pressure from inflation-sensitive consumers in Europe.
Sector drivers shaping Danone’s outlook include: (1) persistent price-elasticity in dairy as European inflation hovers around 5 %; (2) accelerating consumer shift toward plant-based and “better-for-you” products, with the global plant-based market projected to grow at a 12 % CAGR through 2028; and (3) regulatory scrutiny on nutrition labeling and health claims, which can affect the Specialized Nutrition portfolio’s pricing power.
For a deeper quantitative assessment, you may find ValueRay’s analytical tools helpful for digging into Danone’s valuation sensitivities.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 2.85b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 5.69 > 1.0 |
| NWC/Revenue: -1.32% < 20% (prev -3.67%; Δ 2.36% < -1%) |
| CFO/TA 0.17 > 3% & CFO 7.37b > Net Income 2.85b |
| Net Debt (12.92b) to EBITDA (9.30b): 1.39 < 3 |
| Current Ratio: 0.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (644.4m) vs 12m ago 0.45% < -2% |
| Gross Margin: 49.46% > 18% (prev 0.47%; Δ 4899 % > 0.5%) |
| Asset Turnover: 122.3% > 50% (prev 76.08%; Δ 46.26% > 0%) |
| Interest Coverage Ratio: 5.41 > 6 (EBITDA TTM 9.30b / Interest Expense TTM 1.31b) |
Altman Z'' 2.70
| A: -0.02 (Total Current Assets 12.90b - Total Current Liabilities 13.62b) / Total Assets 43.76b |
| B: 0.39 (Retained Earnings 17.23b / Total Assets 43.76b) |
| C: 0.16 (EBIT TTM 7.08b / Avg Total Assets 44.60b) |
| D: 0.44 (Book Value of Equity 12.16b / Total Liabilities 27.84b) |
| Altman-Z'' Score: 2.70 = A |
Beneish M -3.18
| DSRI: 0.63 (Receivables 3.22b/3.25b, Revenue 54.56b/34.57b) |
| GMI: 0.94 (GM 49.46% / 46.67%) |
| AQI: 0.82 (AQ_t 0.56 / AQ_t-1 0.68) |
| SGI: 1.58 (Revenue 54.56b / 34.57b) |
| TATA: -0.10 (NI 2.85b - CFO 7.37b) / TA 43.76b) |
| Beneish M-Score: -3.18 (Cap -4..+1) = AA |
What is the price of BN shares?
Over the past week, the price has changed by +5.04%, over one month by -7.88%, over three months by -10.65% and over the past year by +7.44%.
Is BN a buy, sell or hold?
What are the forecasts/targets for the BN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 78.8 | 13.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 73.2 | 5.9% |
BN Fundamental Data Overview February 03, 2026
P/E Trailing = 27.9298
P/E Forward = 16.8919
P/S = 1.5499
P/B = 2.6677
P/EG = 2.3462
Revenue TTM = 54.56b EUR
EBIT TTM = 7.08b EUR
EBITDA TTM = 9.30b EUR
Long Term Debt = 9.88b EUR (from longTermDebt, last quarter)
Short Term Debt = 3.96b EUR (from shortTermDebt, last quarter)
Debt = 14.54b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.92b EUR (from netDebt column, last quarter)
Enterprise Value = 59.78b EUR (51.26b + Debt 14.54b - CCE 6.01b)
Interest Coverage Ratio = 5.41 (Ebit TTM 7.08b / Interest Expense TTM 1.31b)
EV/FCF = 10.80x (Enterprise Value 59.78b / FCF TTM 5.54b)
FCF Yield = 9.26% (FCF TTM 5.54b / Enterprise Value 59.78b)
FCF Margin = 10.14% (FCF TTM 5.54b / Revenue TTM 54.56b)
Net Margin = 5.22% (Net Income TTM 2.85b / Revenue TTM 54.56b)
Gross Margin = 49.46% ((Revenue TTM 54.56b - Cost of Revenue TTM 27.58b) / Revenue TTM)
Gross Margin QoQ = 50.90% (prev 50.04%)
Tobins Q-Ratio = 1.37 (Enterprise Value 59.78b / Total Assets 43.76b)
Interest Expense / Debt = 2.49% (Interest Expense 362.0m / Debt 14.54b)
Taxrate = 25.78% (373.0m / 1.45b)
NOPAT = 5.25b (EBIT 7.08b * (1 - 25.78%))
Current Ratio = 0.95 (Total Current Assets 12.90b / Total Current Liabilities 13.62b)
Debt / Equity = 0.92 (Debt 14.54b / totalStockholderEquity, last quarter 15.86b)
Debt / EBITDA = 1.39 (Net Debt 12.92b / EBITDA 9.30b)
Debt / FCF = 2.33 (Net Debt 12.92b / FCF TTM 5.54b)
Total Stockholder Equity = 16.64b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.39% (Net Income 2.85b / Total Assets 43.76b)
RoE = 17.12% (Net Income TTM 2.85b / Total Stockholder Equity 16.64b)
RoCE = 26.69% (EBIT 7.08b / Capital Employed (Equity 16.64b + L.T.Debt 9.88b))
RoIC = 19.14% (NOPAT 5.25b / Invested Capital 27.45b)
WACC = 4.37% (E(51.26b)/V(65.80b) * Re(5.08%) + D(14.54b)/V(65.80b) * Rd(2.49%) * (1-Tc(0.26)))
Discount Rate = 5.08% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.20%
[DCF Debug] Terminal Value 85.76% ; FCFF base≈4.59b ; Y1≈4.33b ; Y5≈4.10b
Fair Price DCF = 171.2 (EV 123.18b - Net Debt 12.92b = Equity 110.26b / Shares 644.0m; r=5.90% [WACC]; 5y FCF grow -7.05% → 2.90% )
EPS Correlation: -3.74 | EPS CAGR: -0.65% | SUE: -0.32 | # QB: 0
Revenue Correlation: 46.47 | Revenue CAGR: 6.32% | SUE: 0.67 | # QB: 0
EPS next Year (2026-12-31): EPS=4.07 | Chg30d=+0.036 | Revisions Net=+19 | Growth EPS=+6.8% | Growth Revenue=+3.0%